Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Vergelijkbare regelingen

Dichtstbij qua inhoud — ook over de taalgrens (RVO ↔ EU-calls), via embeddings.

• Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers · EU · 93% · open
• Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases · EU · 91% · open
• Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research · EU · 91% · open
• Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers · EU · 91% · open
• Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines · EU · 91% · open
• Earlier and more precise palliative care · EU · 91% · open